GREENWOOD VILLAGE, Colo., April 14, 2023 (GLOBE NEWSWIRE) -- Advanced Emissions Solutions, Inc. (ADES) (the "Company" or "ADES"), a leader in environmental solutions for power generation, industrial ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The addition of abemaciclib to ...
NASHVILLE, Tenn.--(BUSINESS WIRE)-- SpecialtyCare, the largest and most experienced provider of clinical services to hospitals, announced today that is has completed the acquisition of Advanced ...
A phase I study of weekly topotecan (T) in combination with sorafenib (S) for treatment of relapsed or refractory small cell lung cancer (SCLC). Background: Non-small cell lung cancer (NSCLC) is the ...
Tarrytown, New York, Oct. 15, 2024 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the largest ear, nose, throat, allergy, and audiology practice in the country, is pleased to announce the ...
This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
The investigators of the recent phase III SPIRITS trial found that the addition of cisplatin to S-1 (a fourth generation oral fluoropyrimidine) provided a significant overall survival advantage (P = 0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results